Nicholas P Restifo

Scopus Author ID Loop profile ORCID

Publication Activity (10 Years)

Years Active: 2014-2024
Publications (10 Years): 15

Top Venues

The Journal of experimental medicine

Cancer research communications

Cancer immunology, immunotherapy : CII

Nature medicine

Lyell Immunopharma

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Lyell Immunopharma Jul 01 2019

United States

Executive Vice President for Research

National Cancer Institute

United States

Principal Investigator :: Surgery Branch

Memorial Sloan-Kettering Cancer Center

United States

Research Fellow :: Surgery

Publications

Nicholas P Restifo, Luca Gattinoni
Synthetic soldiers: Turning T cells into immortal warriors. The Journal of experimental medicine 221 (5) (2024)
Nicholas P Restifo, Luca Gattinoni
Synthetic soldiers: Turning T cells into immortal warriors. The Journal of experimental medicine 221 (5) (2024)
Nicholas P Restifo, Luca Gattinoni
Synthetic soldiers: Turning T cells into immortal warriors. The Journal of experimental medicine 221 (5) (2024)
Nicholas P Restifo, Luca Gattinoni
Synthetic soldiers: Turning T cells into immortal warriors. The Journal of experimental medicine 221 (5) (2024)
S M Rafiqul Islam, Takuya Maeda, Naritaka Tamaoki, Meghan L Good, Rigel J Kishton, Biman C Paria, Zhiya Yu, Marta Bosch-Marce, Nicole M Bedanova, Chengyu Liu, Michael J Kruhlak, Nicholas P Restifo, Raul Vizcardo
Reprogramming of Tumor-reactive Tumor-infiltrating Lymphocytes to Human-induced Pluripotent Stem Cells. Cancer research communications 3 (5) (2023)
S M Rafiqul Islam, Takuya Maeda, Naritaka Tamaoki, Meghan L Good, Rigel J Kishton, Biman C Paria, Zhiya Yu, Marta Bosch-Marce, Nicole M Bedanova, Chengyu Liu, Michael J Kruhlak, Nicholas P Restifo, Raul Vizcardo
Reprogramming of Tumor-reactive Tumor-infiltrating Lymphocytes to Human-induced Pluripotent Stem Cells. Cancer research communications 3 (5) (2023)
S M Rafiqul Islam, Takuya Maeda, Naritaka Tamaoki, Meghan L Good, Rigel J Kishton, Biman C Paria, Zhiya Yu, Marta Bosch-Marce, Nicole M Bedanova, Chengyu Liu, Michael J Kruhlak, Nicholas P Restifo, Raul Vizcardo
Reprogramming of Tumor-reactive Tumor-infiltrating Lymphocytes to Human-induced Pluripotent Stem Cells. Cancer research communications 3 (5) (2023)
S M Rafiqul Islam, Takuya Maeda, Naritaka Tamaoki, Meghan L Good, Rigel J Kishton, Biman C Paria, Zhiya Yu, Marta Bosch-Marce, Nicole M Bedanova, Chengyu Liu, Michael J Kruhlak, Nicholas P Restifo, Raul Vizcardo
Reprogramming of Tumor-reactive Tumor-infiltrating Lymphocytes to Human-induced Pluripotent Stem Cells. Cancer research communications 3 (5) (2023)
S M Rafiqul Islam, Takuya Maeda, Naritaka Tamaoki, Meghan L Good, Rigel J Kishton, Biman C Paria, Zhiya Yu, Marta Bosch-Marce, Nicole M Bedanova, Chengyu Liu, Michael J Kruhlak, Nicholas P Restifo, Raul Vizcardo
Reprogramming of Tumor-reactive Tumor-infiltrating Lymphocytes to Human-induced Pluripotent Stem Cells. Cancer research communications 3 (5) (2023)
Fei Mo, Zhiya Yu, Peng Li, Jangsuk Oh, Rosanne Spolski, Liang Zhao, Caleb R Glassman, Tori N Yamamoto, Yun Chen, Filip M Golebiowski, Dalton Hermans, Sonia Majri-Morrison, Lora K Picton, Wei Liao, Min Ren, Xiaoxuan Zhuang, Suman Mitra, Jian-Xin Lin, Luca Gattinoni, Jonathan D Powell, Nicholas P Restifo, K Christopher Garcia, Warren J Leonard
An engineered IL-2 partial agonist promotes CD8+ T cell stemness. Nature 597 (7877) (2021)
Tori N Yamamoto, Rigel J Kishton, Nicholas P Restifo
Developing neoantigen-targeted T cell-based treatments for solid tumors. Nature medicine 25 (10) (2019)
Suman Kumar Vodnala, Robert Eil, Rigel J Kishton, Madhusudhanan Sukumar, Tori N Yamamoto, Ngoc-Han Ha, Ping-Hsien Lee, Min Hwa Shin, Shashank J Patel, Zhiya Yu, Douglas C Palmer, Michael J Kruhlak, Xiaojing Liu, Jason W Locasale, Jing Huang, Rahul Roychoudhuri, Toren Finkel, Christopher A Klebanoff, Nicholas P Restifo
T cell stemness and dysfunction in tumors are triggered by a common mechanism. Science (New York, N.Y.) 363 (6434) (2019)
Anthony L Schwartz, Pulak R Nath, Michael Allgauer, Elizabeth C Lessey-Morillon, John M Sipes, Lisa A Ridnour, Y Maurice Morillon Ii, Zhiya Yu, Nicholas P Restifo, David D Roberts
Antisense targeting of CD47 enhances human cytotoxic T-cell activity and increases survival of mice bearing B16 melanoma when combined with anti-CTLA4 and tumor irradiation. Cancer immunology, immunotherapy : CII 68 (11) (2019)
Ping-Hsien Lee, Tori N Yamamoto, Devikala Gurusamy, Madhusudhanan Sukumar, Zhiya Yu, Jane Hu-Li, Takeshi Kawabe, Arunakumar Gangaplara, Rigel J Kishton, Amanda N Henning, Suman Kumar Vodnala, Ronald N Germain, William E Paul, Nicholas P Restifo
Host conditioning with IL-1β improves the antitumor function of adoptively transferred T cells. The Journal of experimental medicine 216 (11) (2019)
Chryssa Kanellopoulou, Alex B George, Evan Masutani, Jennifer L Cannons, Juan C Ravell, Tori N Yamamoto, Margery G Smelkinson, Ping Du Jiang, Mami Matsuda-Lennikov, Julie Reilley, Robin Handon, Ping-Hsien Lee, J Richard Miller, Nicholas P Restifo, Michael J Lenardo, Pamela L Schwartzberg, Matthew Young, Michael J Lenardo
Mg2+ regulation of kinase signaling and immune function. The Journal of experimental medicine 216 (8) (2019)
Nicholas P Restifo
Big bang theory of stem-like T cells confirmed. Blood 124 (4) (2014)

Nicholas P Restifo.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Nicholas P Restifo